12:00 AM
Aug 09, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BVF-324: Phase III discontinued

Biovail said it discontinued development of BVF-324 to treat premature ejaculation due to slow enrollment in Phase III trials...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >